Please provide your email address to receive an email when new articles are posted on . Patients who received torpialimab in addition to nab-paclitaxel had longer median PFS (8.4 months vs. 5.6 months ...
Please provide your email address to receive an email when new articles are posted on . Results of the phase 3 CHOICE-01 trial, presented during a ASCO Plenary Series session, specifically showed PFS ...
The US Food and Drug Administration (FDA) has approved toripalimab-tpzi (Loqtorz, Coherus BioSciences) in combination with cisplatin and gemcitabine for the first-line treatment of adults with ...
Recent safety and efficacy findings from a phase 1b/2 open-label combination study of ASP-1929 photoimmunotherapy with anti-PD-1 therapy in EGFR-expressing advanced head and neck squamous cell ...
Shanghai Junshi Biosciences (OTCPK:SHJBF) said China's National Medical Products Administration (NMPA) accepted an application seeking expanded approval of toripalimab, in combination with ...
The application is supported by data from the phase 2 POLARIS-02 and phase 3 JUPITER-02 studies. The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License ...
The median overall survival was 31.5 months in the disitamab vedotin-toripalimab arm and 16.9 months in the chemotherapy arm. First-line treatment with disitamab vedotin and toripalimab can improve ...
Shanghai Junshi Biosciences (OTCPK:SHJBF) said its medicine toripalimab met the main goal of event-free survival (EFS) in a phase 3 trial to treat patients with a type of non-small cell lung cancer ...
Clinical efficacy and safety of immune checkpoint inhibitor in combination with regorafenib therapy as second⁃line regimen for patients with unresectable hepatocellular carcinoma. This is an ASCO ...
Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener The latest update ...
Coherus BioSciences, Inc. CHRS and its partner Shanghai Junshi Biosciences Co., Ltd. have announced that the FDA has granted an Orphan Drug designation to their anti-PD-1 antibody, toripalimab, for ...
SK Capital Partners portfolio company Apotex has agreed to acquire the license to the Canadian rights to Toripalimab, an anti-PD-1 monoclonal antibody, from Coherus Biosciences. No financial terms of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results